⛔️Press release⛔️
Phase 2b Study of Oral Omadacycline M. abscessus Pulmonary Disease
➡️ 1st placebo RCT M.abscessus
➡️ Sx-based endpoints = 👍
➡️ Microbiologic endpoints = higher conversion (-) culture, no R
➡️ 12w, omadacycline safe & well-tolerated
#IDsky
https://www.globenewswire.com/news-release/2024/11/08/2977671/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-Line-Data-from-Phase-2b-Study-of-Oral-Omadacycline-OMC-in-Nontuberculous-Mycobacterial-NTM-Abscessus-Pulmonary-Disease.html
Phase 2b Study of Oral Omadacycline M. abscessus Pulmonary Disease
➡️ 1st placebo RCT M.abscessus
➡️ Sx-based endpoints = 👍
➡️ Microbiologic endpoints = higher conversion (-) culture, no R
➡️ 12w, omadacycline safe & well-tolerated
#IDsky
https://www.globenewswire.com/news-release/2024/11/08/2977671/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-Line-Data-from-Phase-2b-Study-of-Oral-Omadacycline-OMC-in-Nontuberculous-Mycobacterial-NTM-Abscessus-Pulmonary-Disease.html
Comments
You are now officially a 100% 🇨🇦 I.D. Doc;
➡️You get cynical with « new »antibiotics availability 😂
I’ve actually had patients go out on IV 💉 because their medical benefits pick up much more of the costs.